Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 4/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 2/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2076945 | 1.00 | CCR2 (0.36) | CCR2USP2SMN1; SMN2RECQLATM | |
| SCHEMBL2076947 | 1.00 | CCR2 (0.36) | CCR2USP2SMN1; SMN2RECQLATM | |
| SCHEMBL2079719 | 0.87 | CCR2 (0.37) | CCR2USP2SMN1; SMN2RECQLATM | |
| SCHEMBL2077004 | 0.81 | CCR2 (0.34) | CCR2USP2SMN1; SMN2RECQLGPR119 | |
| SCHEMBL2076998 | 0.81 | CCR2 (0.34) | CCR2USP2SMN1; SMN2RECQLGPR119 | |
| SCHEMBL2077000 | 0.81 | CCR2 (0.34) | CCR2USP2SMN1; SMN2RECQLGPR119 | |
| SCHEMBL19898535 | 0.80 | NR1H2 (0.43) | NR1H2 | |
| SCHEMBL17686393 | 0.78 | NR1H2 (0.37) | USP2SMN1; SMN2RECQLNR1H2 | |
| SCHEMBL2078105 | 0.75 | NR1H2 (0.35) | SMN1; SMN2NR1H2 | |
| SCHEMBL2078108 | 0.75 | NR1H2 (0.35) | SMN1; SMN2NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906532-B2 | Antiserotonine agents; gastrointestinal disorders; irritable bowel syndrome; central nervous system disorders; Alzheimer's disease; cognition activators; analgesics; cardiovascular disorders; antidiabetic agents; sleep disorders | PFIZER INC. (US) | 2011-03-15 | — | — | US | disclosed |
| EP-1910340-B1 | INDAZOLECARBOXAMIDE DERIVATIVES AS 5HT4 RECEPTOR AGONISTS | PFIZER (US) | 2009-11-18 | — | — | EP | disclosed |
| US-20080269211-A1 | Indazole Derivatives | PFIZER INC | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269211-A1 | Indazole Derivatives | GPR119, HRH4, HTR4 | CCR2 1393/4885USP2 4524/4885SMN1; SMN2 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.